Go Deep
Aytu BioPharma, Inc.
Aytu BioPharma, Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 20,228 | -1.7 | 0.62 | 0.51 | 190.38 |
| Oct 2026 | 20,175 | -1.8 | 0.63 | 0.51 | 193.22 |
| Oct 2026 | 20,318 | -1.7 | 0.60 | 0.51 | 185.84 |
| Oct 2026 | 20,228 | -1.7 | 0.62 | 0.51 | 190.58 |
| Oct 2026 | 20,318 | -1.7 | 0.60 | 0.51 | 185.38 |
| Oct 2026 | 20,282 | -1.7 | 0.61 | 0.51 | 186.89 |
Aytu BioPharma, Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 16,106,000.0 | 12,411,000.0 | 15,165,000.0 | 13,888,000.0 |
| Net Profit | -15,000.0 | -5,618,000.0 | -10,584,000.0 | 1,965,000.0 |
| EPS | 0.0 | -0.5 | -1.1 | 0.2 |
Aytu BioPharma, Inc. Revenue & Profit: Last 5 Years
| Line Item | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|
| Revenue | 57,570,000.0 | 66,382,000.0 | 65,183,000.0 | 107,399,000.0 | — |
| Net Profit | -14,252,000.0 | -13,562,000.0 | -15,844,000.0 | -17,051,000.0 | — |
| EPS | -1.2 | -2.2 | -2.9 | -5.1 | — |
Aytu BioPharma, Inc. Balance Sheet
| Line Item | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|
| Total Assets | 105,007,000.0 | 124,177,000.0 | 118,095,000.0 | 136,463,000.0 | — |
| Total Liabilities | 69,733,000.0 | 105,211,000.0 | 90,379,000.0 | 97,106,000.0 | — |
| Total Equity | 35,274,000.0 | 18,966,000.0 | 27,716,000.0 | 39,357,000.0 | — |
Owes vs Owns
Aytu BioPharma, Inc. owed $0.66 for every $1 it owned in Jun 2026, down from $0.71 in Jun 2023.
| Period | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 |
|---|---|---|---|---|
| Owes vs Owns | 0.66× | 0.85× | 0.77× | 0.71× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Aytu BioPharma, Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Jun 2026
Cash & short-term investments 25.1%Receivables 21.7%Inventory 6.5%Fixed assets (tangible) 1.2%Intangible assets 39.4%Other assets 6.1%
How it's funded — Jun 2026
Short-term debt 7.6%Long-term debt 8.7%Payables 10.7%Other liabilities 39.4%Shareholders' equity 33.6%
| Line Item | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 26.3 | 31.0 | 20.0 | 23.0 |
| Receivables | 22.8 | 31.2 | 23.5 | 28.9 |
| Inventory | 6.9 | 11.4 | 12.1 | 12.0 |
| Fixed assets (tangible) | 1.2 | 1.6 | 1.5 | 3.9 |
| Intangible assets | 41.4 | 42.2 | 52.5 | 59.0 |
| Long-term investments | 0.0 | 0.0 | 0.0 | 0.0 |
| Other assets | 6.4 | 6.8 | 8.4 | 9.7 |
| Liabilities & equity | ||||
| Short-term debt | 7.9 | 10.9 | 4.3 | 1.6 |
| Long-term debt | 9.1 | 10.9 | 10.9 | 14.7 |
| Payables | 11.3 | 10.6 | 10.3 | 13.5 |
| Other liabilities | 41.4 | 72.8 | 64.9 | 67.3 |
| Shareholders' equity | 35.3 | 19.0 | 27.7 | 39.4 |
| Net tangible assets | -6.1 | -23.2 | -24.7 | -19.6 |
Aytu BioPharma, Inc. Cash Flow
| Line Item | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|
| Operating Activities | 3,281,000.0 | -1,937,000.0 | -1,388,000.0 | -5,129,000.0 | — |
| Investing Activities | -29,000.0 | -2,560,000.0 | -329,000.0 | -117,000.0 | — |
| Financing Activities | -7,896,000.0 | 15,443,000.0 | -1,262,000.0 | 8,871,000.0 | — |